相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls
Hassan Kahal et al.
BMC ENDOCRINE DISORDERS (2015)
Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome
Mojca Jensterle et al.
ENDOCRINE RESEARCH (2015)
Liraglutide for the Treatment of Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Placebo-Controlled Trials
Qiang Du et al.
ADVANCES IN THERAPY (2014)
Elevated diastolic blood pressure in insulin-resistant polycystic ovarian syndrome patients
Angelica Maria Holanda Pascoal da Silva et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2014)
Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease
H. Kahal et al.
CLINICAL ENDOCRINOLOGY (2014)
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
Mojca Jensterle Sever et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Epidemiology, diagnosis, and management of polycystic ovary syndrome
Susan M. Sirmans et al.
CLINICAL EPIDEMIOLOGY (2014)
Zinc-α2-Glycoprotein Is Associated With Insulin Resistance in Humans and Is Regulated by Hyperglycemia, Hyperinsulinemia, or Liraglutide Administration
Mengliu Yang et al.
DIABETES CARE (2013)
Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
Evanthia Diamanti-Kandarakis et al.
ENDOCRINE REVIEWS (2012)
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsboll et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
GLP-1 Agonists Exenatide and Liraglutide: A Review About Their Safety and Efficacy
Giuseppe Derosa et al.
CURRENT CLINICAL PHARMACOLOGY (2012)
Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
Julio Rosenstock et al.
DIABETES CARE (2010)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup et al.
LANCET (2009)
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome
Karen Elkind-Hirsch et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on β-cell function in normal living conditions
Andrea Mari et al.
DIABETES CARE (2007)
Insulin resistance in PCOS
Evanthia Diamanti-Kandarakis
ENDOCRINE (2006)
Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy
CJ Glueck et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2005)
Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men
N Pitteloud et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Detecting insulin resistance in polycystic ovary syndrome: Purposes and pitfalls
RS Legro et al.
OBSTETRICAL & GYNECOLOGICAL SURVEY (2004)
The prevalence and features of the polycystic ovary syndrome in an unselected population
R Azziz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Obesity and the polycystic ovary syndrome
A Gambineri et al.
INTERNATIONAL JOURNAL OF OBESITY (2002)
分享论文
